Corrigendum To The Relative Alregime Of 19/2015 January 19, 2015 # Determines New Listings And Price As A Result Of New Therapeutic Indications Of A Medicinal Product For Human Use "simponi (Golimumab). (Resolution No. 130/2015).
Original Language Title: Rettifica della determina n. 19/2015 del 19 gennaio 2015 relativa alregime di rimborsabilita' e prezzo a seguito di nuove indicazioniterapeutiche del medicinale per uso umano «Simponi» (golimumab).(Determina n. 130/2015).
The DIRECTOR-GENERAL having regard to determining # 19/2015 of January 19, 2015 concerning a medicinal product for human use SIMPONI (golimumab) published in the official journal-General series-# 22 of January 28, 2015; Considered the documentation to this Office; Correction: in art. 2 (for the purpose of Classification) where it is written: for the therapeutic indications rheumatoid arthritis (RA), psoriatic arthritis (AP), ankylosing spondylitis (SA): rheumatologist; Read: therapeutic indications for rheumatoid arthritis (RA), psoriatic arthritis (AP), ankylosing spondylitis (SA): rheumatologist, internist; Rome, February 11, 2015 Director General: Pani
Search Translated Laws of Italy
Made in Toronto, Canada
Global-Regulation Inc. is a Canadian federal corporation based in Toronto, Canada.
19 Yorkville Avenue, Suite 300
Toronto, ON, Canada
Our service is entirely run by computer algorithms. Translations are not human-vetted. There may be inaccuracies in information due to our algorithmic extraction of information. Always consult the official source when making use of legal information.